Population-based Study of Cutaneous Malignant Melanoma in the South Region of Portugal: Epidemiological and Clinical Characterization (2016-2017)

Abstract An historical population-based cohort study was conducted aiming to estimate the incidence of cutaneous malignant melanoma in the South Region of Portugal between Jan 2016 and June 2017; to clinically characterize the diagnosed individuals; to describe instituted treatment; and to estimate survival outcomes. Data were extracted from a cancer registry (ROR-Sul) covering 4 800 000 inhabitants (46% of the Portuguese population) and included a total of 789 individuals meeting eligibility criteria. The cumulative incidence rate (18 months) of melanoma was 13.36/100,000 inhabitants and the Age-Standardized Incidence Rate per 100,000 World population was 8.43/100,000 inhabitants. The most common histological subtypes identified were superficial extension, followed by malignant melanoma and nodular melanoma. Most cases were diagnosed in stage I (50.39%), equally distributed by sex and with a median age of 65 years. During the study period, 174 recurrence events were recorded (23.45%) and recurrence-free survival rate was significantly lower in more advanced stages. Patients had a two-fold risk of recurrence/death when in presence of ulcerated tumors [adjusted hazard ratio (adj HR) = 2.28; 95% confidence interval (CI): 1.40–3.70]. Overall survival rate at 3-years was 80.54% (77.58–83.15) and survival was considerably higher for individuals diagnosed at earlier stages. The epidemiologic and clinical characteristics of malignant melanoma patients studied are consistent with international literature. Treatment instituted by Portuguese clinicians is aligned with evidence-based guidelines published. The increase in the incidence rate observed suggests additional public health campaigns are needed to modify behaviours of the Portuguese population and thus reduce their risk.

Download Full-text

Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland

British Journal of Cancer ◽

10.1038/sj.bjc.6600692 ◽

2003 ◽

Vol 88 (1) ◽

pp. 74-78 ◽

Cited By ~ 62

Author(s):

D B McKenna ◽

D Stockton ◽

D H Brewster ◽

V R Doherty

Keyword(s):

Cohort Study ◽

Malignant Melanoma ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Population Based ◽

Cutaneous Malignant Melanoma ◽

Lymphoid Malignancy

Download Full-text

A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence

European Journal of Dermatology ◽

10.1684/ejd.2016.2845 ◽

2016 ◽

Vol 26 (6) ◽

pp. 586-591 ◽

Cited By ~ 2

Author(s):

Marianne Maroti ◽

Eva Ulff ◽

Johan Lyth ◽

Ursula Falkmer

Keyword(s):

Decision Making ◽

Malignant Melanoma ◽

Population Based ◽

Cutaneous Malignant Melanoma ◽

Population Based Study ◽

Support Decision Making ◽

Patterns Of Recurrence

Download Full-text

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

Neuro-Oncology ◽

10.1093/neuonc/noz150 ◽

2019 ◽

Vol 21 (Supplement_5) ◽

pp. v1-v100 ◽

Cited By ~ 273

Author(s):

Quinn T Ostrom ◽

Gino Cioffi ◽

Haley Gittleman ◽

Nirav Patil ◽

Kristin Waite ◽

...

Keyword(s):

United States ◽

Central Nervous System ◽

Nervous System ◽

Survival Rate ◽

Incidence Rate ◽

Relative Survival ◽

The United States ◽

Population Based ◽

Cns Tumors ◽

Relative Survival Rate

AbstractThe Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 23.41 (Malignant AAAIR = 7.08, non-Malignant AAAIR = 16.33). This rate was higher in females compared to males (25.84 versus 20.82), Whites compared to Blacks (23.50 versus 23.34), and non-Hispanics compared to Hispanics (23.84 versus 21.28). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.6% of all tumors), and the most common non-malignant tumor was meningioma (37.6% of all tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0–19 years), the incidence rate of all primary brain and other CNS tumors was 6.06. An estimated 86,010 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US in 2019 (25,510 malignant and 60,490 non-malignant). There were 79,718 deaths attributed to malignant brain and other CNS tumors between 2012 and 2016. This represents an average annual mortality rate of 4.42. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.8%, and the five-year relative survival rate following diagnosis of a non-malignant brain and other CNS tumors was 91.5%.

Download Full-text

Incidence, Mortality, and Spatiotemporal Distribution of Cutaneous Malignant Melanoma Cases Across Canada

Journal of Cutaneous Medicine and Surgery ◽

10.1177/1203475419852048 ◽

2019 ◽

Vol 23 (4) ◽

pp. 394-412 ◽

Cited By ~ 7

Author(s):

Feras M. Ghazawi ◽

Michelle Le ◽

François Lagacé ◽

Janelle Cyr ◽

Nebras Alghazawi ◽

...

Keyword(s):

Malignant Melanoma ◽

Age Groups ◽

Population Based ◽

Geographic Region ◽

Cutaneous Malignant Melanoma ◽

Steady Increase ◽

Mortality Trends ◽

Incidence And Mortality ◽

Future Burden ◽

Melanoma Mortality

Background: We recently reported a steady increase in the incidence and mortality of cutaneous malignant melanoma (CMM) in Canada during 1992-2010. Objectives: The objective of this article is to examine the distribution of Canadian CMM patients at the level of provinces, cities, and forward sortation area (FSA) postal codes. Methods: Using 3 Canadian population-based registries, we conducted an in-depth examination of the incidence and mortality trends for 72 565 Canadian CMM patients over the period 1992-2010. Results: We found that among 20- to 39-year-olds, the incidence of CMM in women (7.17 per 100 000 individuals) was significantly higher than in men (4.60 per 100 000 individuals per year). Women age 80 years and older had an incidence of CMM (58.46 cases per 100 000 women per year) more than 4 times greater than the national average (12.29 cases per 100 000 population per year) and a corresponding high mortality rate (20.18 deaths per 100 000 women per year), when compared with the Canadian melanoma mortality of 2.4 deaths per 100 000 per year. In other age groups men had higher incidence and corresponding melanoma mortality rates. We also studied CMM incidence by province, city, and FSA postal codes and identified several high-incidence communities that were located near the coast/waterfronts. In addition, plotting latitude measures for cities and FSAs vs CMM incidence rate confirmed the inverse relationship between geographical latitude and incidence of melanoma in Canada (slope = –0.22 ± 0.05). Conclusions: This research may help develop sex-, age- and geographic region-specific recommendations to decrease the future burden of CMM in Canada.

Download Full-text

Later Stage at Diagnosis and Worse Survival in Cutaneous Malignant Melanoma Among Men Living Alone: A Nationwide Population-Based Study From Sweden

Journal of Clinical Oncology ◽

10.1200/jco.2013.52.7564 ◽

2014 ◽

Vol 32 (13) ◽

pp. 1356-1364 ◽

Cited By ~ 29

Author(s):

Hanna Eriksson ◽

Johan Lyth ◽

Eva Månsson-Brahme ◽

Margareta Frohm-Nilsson ◽

Christian Ingvar ◽

...

Keyword(s):

Malignant Melanoma ◽

Clinical Stage ◽

Age Groups ◽

Population Based ◽

Cutaneous Malignant Melanoma ◽

Stage I ◽

Stage Ii ◽

Living Alone ◽

Stage At Diagnosis ◽

Population Based Study

Purpose To investigate the association between cohabitation status, clinical stage at diagnosis, and disease-specific survival in cutaneous malignant melanoma (CMM). Methods This nationwide population-based study included 27,235 patients from the Swedish Melanoma Register diagnosed with a primary invasive CMM between 1990 and 2007 and linked data to nationwide, population-based registers followed up through 2012. Results After adjustment for age at diagnosis, level of education, living area, period of diagnosis, and tumor site, the odds ratios (ORs) of higher stage at diagnosis were significantly increased among men living alone versus men living with a partner (stage II v stage I: OR, 1.42; 95% CI, 1.29 to 1.57; stage III or IV v stage I: OR, 1.43; 95% CI, 1.14 to 1.79). The OR for stage II versus stage I disease was also increased among women living alone (OR, 1.15; 95% CI, 1.04 to 1.28). After adjustments for the factors listed earlier, the CMM-specific survival was significantly decreased among men living alone (hazard ratio [HR] for death, 1.48; 95% CI, 1.33 to 1.65; P < .001). After additional adjustments for all potential and established prognostic factors, CMM-specific survival among men living alone versus men living with a partner remained significantly decreased (HR, 1.31; 95% CI, 1.18 to 1.46; P < .001), suggesting a residual adverse effect on survival not accounted for by these parameters. Conclusion In all age groups among men, living alone is significantly associated with reduced CMM-specific survival, partially attributed to a more advanced stage at diagnosis. This emphasizes the need for improved prevention and early detection strategies for this group.

Download Full-text